Xarelto is a prescription pain medication first approved by the FDA in July of 2011. The drug is co-marketed by Bayer and Johnson & Johnson. The medication is prescribed for three primary purposes: reducing the risk of strokes and blood clots after a diagnosis of atrial fibrillation; reducing the risk of blood clot and stroke when patients undergo knee replacement or hip replacement procedures; and treatment of pulmonary embolisms or deep vein thrombosis.
Individuals taking Xarelto have suffered various bleeding events leading to death. Lawyers are pursuing cases where Xarelto users have suffered injuries such as pulmonary embolism, deep vein thrombosis, gastrointestinal hemorrhage and hemorrhage and death.